Galectin-3与MMP-9在膀胱尿路上皮细胞癌中的表达及临床意义

发布时间：2018-05-30 14:12

本文选题：膀胱尿路上皮细胞癌 + 半乳糖凝集素-3　；参考：《安徽医科大学》2014年硕士论文

【摘要】：目的通过检测半乳糖凝集素-3（Galectin-3）和基质金属蛋白酶-9（MMP-9）在膀胱尿路上皮细胞癌（BUCC）组织中的表达情况，分析两者与BUCC临床病理参数的关系，，探讨Galectin-3和MMP-9在BUCC的发生、发展及预后的临床意义。方法采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶（S-P）方法，对67例BUCC（其中T1期17例，T2期23例，T3期20例，T4期7例）和12例正常膀胱组织中Galectin-3和MMP-9的表达进行检测，并计数BUCC肿瘤组织的微血管密度（MVD）。结合临床病理数据，应用统计学方法分析两者与BUCC的肿瘤大小、病理分级、临床分期、淋巴转移、复发性和MVD等，以及与BUCC患者的年龄、性别和术后生存率的关系。结果BUCC组织中，Galectin-3和MMP-9阳性表达率为62.69%和73.13%，分别高于在正常膀胱组织的16.67%和0.00%，差异有统计学意义（P0.05）；BUCC临床分期及病理分级越高，两者阳性表达率越高，有淋巴结转移者较无转移者阳性表达率高，复发者较初发者高，差异有统计学意义（P0.05）；Galectin-3和MMP-9阳性表达率在不同性别、不同年龄和不同肿瘤大小之间无明显差异，无统计学意义（P0.05）。MMP-9在Galectin-3表达阳性的BUCC中的阳性表达率较Galectin-3阴性中的高；相应的，Galectin-3在MMP-9表达阳性的BUCC组织中的阳性表达率较MMP-9阴性中的高。两者在BUCC中表达呈正相关，存在统计学意义（χ2=22.284，列联系数r=0.500，P 0.05）。MVD在Galectin-3和MMP-9呈现阳性表达的BUCC组织中高于阴性者，差异有统计学意义（P 0.05）。Galectin-3和MMP-9表达阳性的患者术后5年生存率低于表达阴性者，差异有统计学意义（P0.05）。结论Galectin-3和MMP-9与BUCC病理学分级、临床分期、淋巴结转移及复发密切相关，可能与BUCC的发生、进展、侵犯及转移有关，且两者可能存在某种协同效应；两者对BUCC组织肿瘤血管生成可能具有某种上调作用，对BUCC发生及发展机制研究可能有科研价值；两者与患者术后生存率密切相关，可能成为BUCC手术治疗的有效预后指标。
[Abstract]:Objective to investigate the expression of Galectin-3 (galectin-3) and matrix metalloproteinase-9 (MMP-9) in bladder urinary tract epithelial cell carcinoma (BUCC), and to analyze the relationship between them and the clinicopathological parameters of BUCC, and to explore the occurrence of Galectin-3 and MMP-9 in BUCC. Clinical significance of development and prognosis. Methods the expression of Galectin-3 and MMP-9 in 67 cases of bucca (17 cases of T 1, 23 cases of stage T 3, 7 cases of phase 4 of T 3) and 12 cases of normal bladder tissues were detected by immunohistochemical streptomyces biotin-peroxidase S-P method. The microvessel density of BUCC tumor tissue was counted. Combined with clinicopathological data, the relationship between tumor size, pathological grade, clinical stage, lymphatic metastasis, recurrence and MVD, and age, sex and postoperative survival rate of BUCC patients were analyzed by statistical method. Results the positive expression rates of Galectin-3 and MMP-9 in BUCC were 62.69% and 73.13, respectively, which were higher than those in normal bladder tissue (16.67% and 0.005%, respectively). The higher the clinical stage and pathological grade were, the higher the positive expression rate was. The positive expression rate of Galectin-3 and MMP-9 in patients with lymph node metastasis was higher than that in patients with lymph node metastasis, and the positive rates of Galectin-3 and MMP-9 in patients with recurrent lymph nodes were higher than those without metastasis. There was no significant difference in the positive expression rates of Galectin-3 and MMP-9 between different genders, different ages and different tumor sizes. The positive expression rate of MMP-9 in Galectin-3 positive BUCC was higher than that in Galectin-3 negative BUCC, and the positive rate of MMP-9 positive BUCC was higher than MMP-9 negative. There was a positive correlation between them in BUCC and there was a significant difference between them (蠂 ~ 2, P = 22.284, r = 0.500 P 0.05).MVD). The positive expression of P 0.05).MVD in Galectin-3 and MMP-9 was higher than that in the negative ones. The 5-year survival rate of patients with positive expression of P 0.05).Galectin-3 and MMP-9 was significantly lower than that of patients with negative expression of P 0.05).Galectin-3 and MMP-9, and the difference was statistically significant (P 0.05). Conclusion Galectin-3 and MMP-9 are closely related to the pathological grading, clinical stage, lymph node metastasis and recurrence of BUCC, and may be related to the occurrence, progression, invasion and metastasis of BUCC, and there may be some synergistic effect between them. Both of them may have some up-regulation effect on tumor angiogenesis in BUCC tissues, and may be of scientific value in the study of the pathogenesis and development of BUCC, and they are closely related to the survival rate of the patients after operation, and may be an effective prognostic index for the treatment of BUCC.
【学位授予单位】：安徽医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.14

【参考文献】